Glycoprotein 41 (gp41) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glycoprotein 41 (gp41) - Pipeline Review, H2 2017

Summary

Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together. 

Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 6 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS). 

The latest report Glycoprotein 41 (gp41) - Pipeline Review, H2 2017, outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Glycoprotein 41 (gp41) - Overview 7
Glycoprotein 41 (gp41) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Glycoprotein 41 (gp41) - Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development 20
Amunix Operating Inc 20
Frontier Biotechnologies Inc 20
InnaVirVax SA 21
Longevity Biotech Inc 21
Mymetics Corp 22
Navigen Inc 22
Osel Inc 23
Pharis Biotec GmbH 23
Glycoprotein 41 (gp41) - Drug Profiles 24
CPT-31 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
DS-007 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Enfuvirtide-XTEN - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
FB-006M - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
HIV-1 vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LBT-5001 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
MYMV-101 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MYMV-201 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Recombinant Peptides for HIV-1 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
STOP-3S - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Synthetic Peptide to Target gp41 for HIV Infection - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
VAC-02 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
VAC-3S - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
VIR-576 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Glycoprotein 41 (gp41) - Dormant Products 48
Glycoprotein 41 (gp41) - Discontinued Products 50
Glycoprotein 41 (gp41) - Product Development Milestones 51
Featured News & Press Releases 51
Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines 51
Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen's HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting 51
Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development 52
Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate 53
Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial 53
May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US 54
Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed 55
Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic 56
Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine 57
Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics 58
Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry" 58
Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection 59
Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013 60
Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE 60
Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Number of Products under Investigation by Universities/Institutes, H2 2017 13
Products under Investigation by Universities/Institutes, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by Amunix Operating Inc, H2 2017 20
Pipeline by Frontier Biotechnologies Inc, H2 2017 20
Pipeline by InnaVirVax SA, H2 2017 21
Pipeline by Longevity Biotech Inc, H2 2017 21
Pipeline by Mymetics Corp, H2 2017 22
Pipeline by Navigen Inc, H2 2017 22
Pipeline by Osel Inc, H2 2017 23
Pipeline by Pharis Biotec GmbH, H2 2017 23
Dormant Projects, H2 2017 48
Discontinued Products, H2 2017 50